Beta Bionics, Inc. (BBNX) Stock Price & Analysis
Beta Bionics, Inc. (BBNX) fell 0.46% to USD 19.33 as of September 9, 2026 at 11:43 UTC, according to Nexqual real-time market data.
BBNX last closed at USD 19.42; the session ranged USD 18.75–19.52 on volume of 900,487 shares. Market capitalization is $869.65M, with a 52-week range of USD 8.8–32.71 (NGM). Source: Nexqual, September 9, 2026 at 11:43 UTC.
Key Statistics (as of September 9, 2026 at 11:43 UTC)
| Price | USD 19.33 |
|---|---|
| Change | ▼ 0.46% (down) |
| Previous Close | USD 19.42 |
| Open | USD 19.18 |
| Day Range | USD 18.75 – 19.52 |
| 52-Week Range | USD 8.8 – 32.71 |
| Volume | 900,487 shares |
| Market Cap | $869.65M |
| Exchange | NGM |
Technical Analysis (BBNX)
Nexqual's technical model rates BBNX "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of September 9, 2026 at 11:43 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 55.75 (neutral) |
| vs SMA50 | Above (USD 17.22) |
| MACD | 0.85 (positive) |
Analyst Ratings (BBNX)
Wall Street analysts rate BBNX "Buy" based on 11 analysts, with a mean price target of USD 20.31 (range USD 14–30.4), per Nexqual as of September 9, 2026 at 11:43 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 20.31 |
| High Target | USD 30.4 |
| Low Target | USD 14 |
| Buy / Hold / Sell | 8 / 4 / 0 |
Earnings (BBNX)
| Next Earnings Date | 2026-10-27 |
|---|---|
| EPS Estimate | USD -0.51 |
| Revenue Estimate | $35.04M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.36 vs est -0.56 ▲ beat |
| 2026-03-31 | USD -0.36 vs est -0.45 ▲ beat |
| 2025-12-31 | USD -0.19 vs est -0.38 ▲ beat |
| 2025-09-30 | USD -0.33 vs est -0.41 ▲ beat |
Source: Nexqual, September 9, 2026 at 11:43 UTC.
Financials & Fundamentals (BBNX)
| Total Revenue | $119.01M |
|---|---|
| Revenue Growth (YoY) | +37.80% |
| Gross Margin | +58.31% |
| Operating Margin | -79.90% |
| Profit Margin | -61.31% |
| ROE | -26.16% |
| Debt / Equity | 2.54 |
| Current Ratio | 8.88 |
| Total Cash | $180.49M |
| Total Debt | $6.51M |
| Free Cash Flow | $-40.29M |
Source: Nexqual, September 9, 2026 at 11:43 UTC.
Financial Health Score (BBNX)
Nexqual rates Beta Bionics, Inc.'s overall financial health "Mixed" across five dimensions, as of September 9, 2026 at 11:43 UTC.
| Growth | Strong — Revenue +54% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 58%, operating -80% |
| Balance Sheet | Strong — $180M cash vs $7M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$40M, burning cash |
| Efficiency | Critical — ROE -26%, ROA -16.7% |
Ownership (BBNX)
| Insider Ownership | +1.11% |
|---|---|
| Institutional Ownership | +112.11% |
| Shares Outstanding | 44.99M |
| Float | 26.48M |
| Short % of Float | +16.74% |
Source: Nexqual, September 9, 2026 at 11:43 UTC.
Leadership (BBNX)
Beta Bionics, Inc. is led by Sean T. Saint PE (age 49), President, CEO & Director, per Nexqual as of September 9, 2026 at 11:43 UTC.
| President, CEO & Director | Sean T. Saint PE (age 49) |
|---|---|
| CFO, Treasurer & Secretary | Stephen H. Feider (age 35) |
| Chief Product Officer | Mike Mensinger (age 47) |
| Vice President of Operations | David Henderson |
Major Backers & Investors (BBNX)
Notable institutional backers of Beta Bionics, Inc. include Eventide Asset Management LLC, MUTUAL FUND SERIES TRUST-Eventide Gilead Fund, Soleus Capital Management, L.P., according to Nexqual as of September 9, 2026 at 11:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Eventide Asset Management LLC | 13.9% |
| MUTUAL FUND SERIES TRUST-Eventide Gilead Fund | 13.42% |
| Soleus Capital Management, L.P. | 9.77% |
| Morgan Stanley | 9.48% |
| Sands Capital Alternatives, LLC | 8.24% |
| Point72 Asset Management, L.P. | 5.01% |
| Vestal Point Capital, LP | 3.56% |
| RTW Investments LP | 3.33% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.62% |
| Vanguard Group | 7.83% |
Source: Nexqual, September 9, 2026 at 11:43 UTC.
From Beta Bionics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.
- It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older.
- The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes.
- It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KMTS | Kestra Medical Technologies, Lt | USD 25.64 | ▲ 1.97% |
| CBLL | CeriBell, Inc. | USD 24.31 | ▼ 1.06% |
| MAZE | Maze Therapeutics, Inc. | USD 26.37 | ▲ 1.93% |
| SION | Sionna Therapeutics, Inc. | USD 7.3 | ▲ 8.15% |
| HTFL | Heartflow, Inc. | USD 47.75 | ▼ 3.94% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 11:43 UTC. This page is informational and not investment advice.